Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) Short Interest Update

Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) saw a large growth in short interest during the month of August. As of August 14th, there was short interest totaling 17,905 shares, a growth of 102.8% from the July 30th total of 8,827 shares. Based on an average daily volume of 102,216 shares, the days-to-cover ratio is currently 0.2 days. Approximately 0.6% of the company’s stock are short sold.

Invesco Biotechnology & Genome ETF Stock Performance

Shares of NYSEARCA:PBE traded down $2.22 during midday trading on Friday, reaching $96.32. 7,044 shares of the company’s stock traded hands, compared to its average volume of 13,032. Invesco Biotechnology & Genome ETF has a one year low of $67.69 and a one year high of $98.82. The company has a market cap of $303.41 million, a price-to-earnings ratio of 20.44 and a beta of 0.70. The stock has a 50 day moving average of $92.06 and a 200 day moving average of $84.78.

Hedge Funds Weigh In On Invesco Biotechnology & Genome ETF

A number of institutional investors and hedge funds have recently made changes to their positions in PBE. Northwestern Mutual Wealth Management Co. raised its stake in shares of Invesco Biotechnology & Genome ETF by 9,169.5% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 342,971 shares of the company’s stock worth $28,175,000 after buying an additional 339,271 shares during the period. LPL Financial LLC increased its holdings in Invesco Biotechnology & Genome ETF by 5.0% in the 4th quarter. LPL Financial LLC now owns 97,304 shares of the company’s stock worth $7,994,000 after acquiring an additional 4,617 shares in the last quarter. United Capital Financial Advisors LLC purchased a new stake in Invesco Biotechnology & Genome ETF in the 3rd quarter worth approximately $5,946,000. Royal Bank of Canada raised its stake in Invesco Biotechnology & Genome ETF by 22.3% during the 1st quarter. Royal Bank of Canada now owns 75,402 shares of the company’s stock worth $4,783,000 after acquiring an additional 13,767 shares during the period. Finally, Bank of America Corp DE lifted its holdings in Invesco Biotechnology & Genome ETF by 2.5% during the third quarter. Bank of America Corp DE now owns 59,918 shares of the company’s stock valued at $4,186,000 after purchasing an additional 1,453 shares in the last quarter.

About Invesco Biotechnology & Genome ETF

PowerShares Dynamic Biotechnology & Genome Portfolio (the Fund) is based on the Dynamic Biotechnology & Genome Intellidex Index (the Index). The Fund seeks investment results that correspond generally to the price and yield of the Index. The Index consists of stocks of 30 the United States biotechnology and genome companies. The Fund will normally invest at least 90% of its total assets in common stocks that consists of the Index. The Index is designed to provide capital appreciation by evaluating companies based on a variety of investment merit criteria, including fundamental growth, stock valuation, investment timeliness and risk factors.